RightAnswer Knowledge Solutions Search Results for Pramlintide

New Search  |  Search Results (Pramlintide)  |  Index of Example Chemical Results Pages
register now
RightAnswer Knowledge Solutions provides access to hundreds of data sources. Our premier and proprietary sources include fully-researched documents from well-established experts in the chemical and HazMat fields.

A search in our system for this chemical would return results – all in one place -- in the following categories from the listed data sources.
  • Chemical Identification
  • Environmental Hazards
  • First Aid/Medical Treatment
  • Physical/Chemical Properties
  • Regulatory/Standards/Labels
  • Report Abstracts and Studies
  • Reproductive Risk
  • Toxicology/Health Hazards/Exposure
Example of Acute Exposure data from MEDITEXT.

RightAnswer Proprietary Data Sources:

MEDITEXT® Documentshelp

All Other Data Sources:

DART Documentshelp
REPROTOX® Documentshelp
RTECS® Registryhelp
TERIS Documentshelp
MSDSonline®help

ChemID External Links:

Other Government Links Searched via RegsKnowledge:

State Environmental Regulationshelp
CFR Regulationshelp

Example Content from MEDITEXT for Pramlintide:


Please note: this is an extract of information from a larger document. Full document and details are available by subscription.

ACUTE EXPOSURE INFORMATION

  1. WITH THERAPEUTIC USE
    1. The most frequently reported adverse effects, following therapeutic administration of pramlintide, include nausea, vomiting, anorexia, and headache.
    1. Concomitant administration of pramlintide with one or more antidiabetic agents (eg, insulin, sulfonylureas) increases the risk of hypoglycemia. Severe hypoglycemia associated with pramlintide will generally occur within 3 hours after pramlintide administration.
  1. WITH POISONING/EXPOSURE
    1. Pramlintide overdose information is limited. Severe nausea, vomiting, diarrhea, vasodilatation, and dizziness were reported in healthy volunteers following administration of single 10-mg doses.
    1. Hypoglycemia is not expected after administration of pramlintide alone, but may develop if pramlintide is administered with insulin or other hypoglycemic agents.
© 2011-2025 RightAnswer.com, Inc. and/or its licensors. All rights reserved. No claim to original U.S. Govt. works.